What's Happening?
Pfizer Inc. has announced promising results from its Phase 3 TALAPRO-3 study, which evaluated the combination of TALZENNA (talazoparib) and XTANDI (enzalutamide) in men with metastatic castration-sensitive
prostate cancer (mCSPC) with homologous recombination repair (HRR) gene mutations. The study demonstrated a 52% reduction in the risk of radiographic progression or death compared to placebo plus XTANDI. At three years, the radiographic progression-free survival (rPFS) rate was 77% for patients treated with the combination, compared to 56% for those on placebo. The study, presented at the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting, highlights the potential of this combination to improve outcomes for patients with HRR gene-altered prostate cancer.
Why It's Important?
The findings from the TALAPRO-3 study are significant as they offer a new potential treatment option for patients with HRR gene-mutated mCSPC, a group that often faces poorer outcomes. The combination of TALZENNA and XTANDI could delay the progression to castration-resistant disease, which is the most lethal phase of prostate cancer. This development underscores the importance of genetic testing in routine care and could lead to changes in clinical practice, providing patients with more time before disease progression compared to current standards.
What's Next?
Pfizer is discussing the results with global health authorities to potentially expand the indication for the TALZENNA and XTANDI combination. The trial is ongoing, and overall survival will be formally assessed at the final analysis. The combination is already approved in over 60 countries for other indications, and these new findings could lead to broader approval and use in treating HRR gene-mutated mCSPC.
